Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII

Molecular Therapy

Volumn 19, Issue 2, 2011, Pages 302-309

  Spencer, H Trent ^a   Denning, Gabriela ^b   Gautney, Richard E ^b   Dropulic, Boro ^c   Roy, Andre J ^c   Baranyi, Lajos ^c   Gangadharan, Bagirath ^a   Parker, Ernest T ^a   Lollar, Pete ^a   Doering, Christopher B ^a  

^a CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^b Expression Therapeutics   (United States)

^c Lentigen Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ET 801I; LENTIVIRUS VECTOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOENGINEERING; BIOSYNTHESIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG PURIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; GENE SEQUENCE; GLYCOSYLATION; HEMOPHILIA A; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN INTERACTION; SEQUENCE HOMOLOGY; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM;

MAMMALIA; SUS;

EID: 79551624145     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.239     Document Type: Article

References (21)

1. Garber, K (2000). rFactor VIII deficit questioned. Nat Biotechnol 18: 1133.
2. Kaufman, RJ, Pipe, SW, Tagliavacca, L, Swaroop, M and Moussalli, M (1997). Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis 8 Suppl 2: S3-14.
3. Swaroop, M, Moussalli, M, Pipe, SW and Kaufman, RJ (1997). Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII. J Biol Chem 272: 24121-24124.
4. Miao, HZ, Sirachainan, N, Palmer, L, Kucab, P, Cunningham, MA, Kaufman, RJ et al. (2004). Bioengineering of coagulation factor VIII for improved secretion. Blood 103: 3412-3419.
5. Doering, CB, Denning, G, Dooriss, K, Gangadharan, B, Johnston, JM, Kerstann, KW et al. (2009). Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A. Mol Ther 17: 1145-1154.
6. Doering, CB, Healey, JF, Parker, ET, Barrow, RT and Lollar, P (2002). High level expression of recombinant porcine coagulation factor VIII. J Biol Chem 277: 38345-38349. (Pubitemid 35154689)
7. Doering, CB, Healey, JF, Parker, ET, Barrow, RT and Lollar, P (2004). Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion. J Biol Chem 279: 6546-6552.
8. Doering, CB, Healey, JF, Parker, ET, Barrow, RT and Lollar, P (2002). High level expression of recombinant porcine coagulation factor VIII. J Biol Chem 277: 38345-38349. (Pubitemid 35154689)
9. Parker, ET, Healey, JF, Barrow, RT, Craddock, HN and Lollar, P (2004). Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood 104: 704-710.
10. Healey, JF, Parker, ET, Barrow, RT, Langley, TJ, Church, WR and Lollar, P (2009). The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice. Thromb Haemost 102: 35-41.
11. Pace, CN, Vajdos, F, Fee, L, Grimsley, G and Gray, T (1995). How to measure and predict the molar absorption coefficient of a protein. Protein Sci 4: 2411-2423.
12. Doering, C, Parker, ET, Healey, JF, Craddock, HN, Barrow, RT and Lollar, P (2002). Expression and characterization of recombinant murine factor VIII. Thromb Haemost 88: 450-458. (Pubitemid 35021604)
13. Boedeker, BG (2001). Production processes of licensed recombinant factor VIII preparations. Semin Thromb Hemost 27: 385-394.
14. Lollar, P and Parker, CG (1990). pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem 265: 1688-1692.
15. Lollar, P and Parker, ET (1991). Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J Biol Chem 266: 12481-12486.
16. Lollar, P, Parker, ET and Fay, PJ (1992). Coagulant properties of hybrid human/porcine factor VIII molecules. J Biol Chem 267: 23652-23657.
17. Pipe, SW, Eickhorst, AN, McKinley, SH, Saenko, EL and Kaufman, RJ (1999). Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood 93: 176-183.
18. Pipe, SW, Saenko, EL, Eickhorst, AN, Kemball-Cook, G and Kaufman, RJ (2001). Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood 97: 685-691.
19. Parker, ET, Doering, CB and Lollar, P (2006). A1 subunit-mediated regulation of thrombin-activated factor VIII A2 subunit dissociation. J Biol Chem 281: 13922-13930.
20. Dooriss, KL, Denning, G, Gangadharan, B, Javazon, EH, McCarty, DA, Spencer, HT et al. (2009). Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A. Hum Gene Ther 20: 465-478.
21. Gitschier, J, Wood, WI, Goralka, TM, Wion, KL, Chen, EY, Eaton, DH et al. (1984). Characterization of the human factor VIII gene. Nature 312: 326-330.